Monjuvi (Tafasitamab-cxix)
- Medicine Name: Monjuvi
- Generic Name: Tafasitamab-cxix
- Dosage Form & Strength: Injection: 200 mg as Lyophilized Powder in Single Dose Vial for Reconstitution
- Manufactured By: Morphosys US Inc.
- Cycle 1: Days 1’st, 4’th, 8’th, 15’th and 22’nd of the 28-day cycle.
- Cycles 2 and 3: Days 1’st, 8’th, 15’th and 22’nd of each 28-day cycle.
- Cycle 4 and beyond: Days 1’st and 15’th of each 28-day cycle.
- The monjuvi 200 mg can cause infusion-related reactions. Premedicate patients prior to initiating monjuvi infusion. Assess patients frequently during infusion.
- Tafasitamab-cxix can cause serious/severe myelosuppression, including thrombocytopenia, neutropenia, and anemia. Monitor CBC before each treatment cycle and throughout therapy. Evaluate patients with neutropenia for signs of infection.
- Fatal and serious infections, including opportunistic infections, appeared in patients while on treatment with monjuvi injection and after the final dose. Assess patients for signs and symptoms of infection and manage as appropriate.
- Based on its working, Tafasitamab-cxix may cause fetal B-cell depletion if administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive age to use apt contraception during treatment and for at least 3 months after the final dose.
What documents are required to import MONJUVI to India?
MONJUVI (tafasitamab-cxix) can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is MONJUVI available in India?
MONJUVI (Tafasitamab-cxix Injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and AustraliaEnsuring 100% transparency.
MONJUVI (Tafasitamab-cxix 200 mg injection) can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of MONJUVI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for monjuvi price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source MONJUVI (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.